DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Editas Medicine
Editas Medicine
Gene Editing Workshop
Market Deep Dive Report CRISPR Therapeutics June 2020
Editas Medicine Announces Second Quarter 2019 Results and Update
Innovative Startups 2013
Editas Medicine Announces Third Quarter 2020 Results and Update
CRISPR Genome-Editing
Editas Medicine Announces First Quarter 2018 Results and Update
Editas Medicine Corporate Presentation
Editas Medicine Announces Third Quarter 2019 Results and Update
Zafgen Charts Unique Path to Obesity Approval
Landscape In… » Gene Therapy Companies
UNITED STATES SECURITIES and EXCHANGE COMMISSION Editas
LYZZ Capital 85
UNITED STATES SECURITIES and EXCHANGE COMMISSION FORM 8‑K Editas Medicine, Inc
INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant As Specified in Its Charter)
Moving Genome Editing to the Clinic: from Technology To
2020 Annual Meeting Scientific Program Committee All Relationships Are Considered Compensated
MORGAN L. MAEDER, Phd 41 Spring Park Ave., Jamaica Plain, MA 02130 (617) 460-4420
[email protected]
Top View
UNITED STATES SECURITIES and EXCHANGE COMMISSION FORM 8-K Editas Medicine, Inc
Xconomyawardsprogram.Pdf
36Th Annual J.P. Morgan Healthcare Conference